BACKGROUND AND PURPOSE: The aim of this study was to determine whether the apelin/APJ system is altered in human cardiovascular disease by investigating whether the expression of apelin or its receptor is altered at the protein level. EXPERIMENTAL APPROACH: Radioligand binding studies were used to determine apelin receptor density in human cardiac tissues. Apelin peptide levels in cardiovascular tissues were determined by radioimmunoassay. In vitro pharmacology was used to assess vasoactive properties of apelin in human coronary artery. Localization of apelin and its receptor in coronary artery was determined using immunohistochemistry. KEY RESULTS: Apelin receptor density was significantly decreased in left ventricle from patients with dilated cardiomyopathy or ischaemic heart disease compared with controls, but apelin peptide levels remained unchanged. Apelin was up-regulated in human atherosclerotic coronary artery and this additional peptide localized to the plaque, colocalizing with markers for macrophages and smooth muscle cells. Apelin potently constricted human coronary artery. CONCLUSIONS AND IMPLICATIONS: We have detected changes in the apelin/APJ system in human diseased cardiac and vascular tissue. The decrease in receptor density in heart failure may limit the positive inotropic actions of apelin, contributing to contractile dysfunction. The contribution of the increased apelin levels in atherosclerotic coronary artery to disease progression remains to be determined. These data suggest a potential role for the apelin/APJ system in human cardiovascular disease.
BACKGROUND AND PURPOSE: The aim of this study was to determine whether the apelin/APJ system is altered in humancardiovascular disease by investigating whether the expression of apelin or its receptor is altered at the protein level. EXPERIMENTAL APPROACH: Radioligand binding studies were used to determine apelin receptor density in human cardiac tissues. Apelin peptide levels in cardiovascular tissues were determined by radioimmunoassay. In vitro pharmacology was used to assess vasoactive properties of apelin in human coronary artery. Localization of apelin and its receptor in coronary artery was determined using immunohistochemistry. KEY RESULTS:Apelin receptor density was significantly decreased in left ventricle from patients with dilated cardiomyopathy or ischaemic heart disease compared with controls, but apelin peptide levels remained unchanged. Apelin was up-regulated in humanatherosclerotic coronary artery and this additional peptide localized to the plaque, colocalizing with markers for macrophages and smooth muscle cells. Apelin potently constricted human coronary artery. CONCLUSIONS AND IMPLICATIONS: We have detected changes in the apelin/APJ system in human diseased cardiac and vascular tissue. The decrease in receptor density in heart failure may limit the positive inotropic actions of apelin, contributing to contractile dysfunction. The contribution of the increased apelin levels in atherosclerotic coronary artery to disease progression remains to be determined. These data suggest a potential role for the apelin/APJ system in humancardiovascular disease.
Authors: Keiji Kuba; Liyong Zhang; Yumiko Imai; Sara Arab; Manyin Chen; Yuichiro Maekawa; Michael Leschnik; Andreas Leibbrandt; Mato Markovic; Mato Makovic; Julia Schwaighofer; Nadine Beetz; Renata Musialek; G Greg Neely; Vukoslav Komnenovic; Ursula Kolm; Bernhard Metzler; Romeo Ricci; Hiromitsu Hara; Arabella Meixner; Mai Nghiem; Xin Chen; Fayez Dawood; Kit Man Wong; Renu Sarao; Eva Cukerman; Akinori Kimura; Lutz Hein; Johann Thalhammer; Peter P Liu; Josef M Penninger Journal: Circ Res Date: 2007-08-02 Impact factor: 17.367
Authors: James C Simpkin; Derek M Yellon; Sean M Davidson; Shiang Y Lim; Abigail M Wynne; Christopher C T Smith Journal: Basic Res Cardiol Date: 2007-08-13 Impact factor: 17.165
Authors: B F O'Dowd; M Heiber; A Chan; H H Heng; L C Tsui; J L Kennedy; X Shi; A Petronis; S R George; T Nguyen Journal: Gene Date: 1993-12-22 Impact factor: 3.688
Authors: Ahmad Y Sheikh; Hyung J Chun; Alexander J Glassford; Ramendera K Kundu; Ingo Kutschka; Diego Ardigo; Stephen L Hendry; Roger A Wagner; Mary M Chen; Ziad A Ali; Patrick Yue; Diem T Huynh; Andrew J Connolly; Marc P Pelletier; Philip S Tsao; Robert C Robbins; Thomas Quertermous Journal: Am J Physiol Heart Circ Physiol Date: 2007-09-28 Impact factor: 4.733
Authors: Veli-Pekka Ronkainen; Jarkko J Ronkainen; Sandra L Hänninen; Hanna Leskinen; Jorge L Ruas; Teresa Pereira; Lorenz Poellinger; Olli Vuolteenaho; Pasi Tavi Journal: FASEB J Date: 2007-03-06 Impact factor: 5.191
Authors: Enrica Golia; Giuseppe Limongelli; Francesco Natale; Fabio Fimiani; Valeria Maddaloni; Pina Elvira Russo; Lucia Riegler; Renatomaria Bianchi; Mario Crisci; Gaetano Di Palma; Paolo Golino; Maria Giovanna Russo; Raffaele Calabrò; Paolo Calabrò Journal: World J Cardiol Date: 2014-07-26
Authors: Anthony P Davenport; Conor C G Scully; Chris de Graaf; Alastair J H Brown; Janet J Maguire Journal: Nat Rev Drug Discov Date: 2020-03-19 Impact factor: 84.694